Role of Biotransformation Reactions in Prenatal and Postnatal Chemical Toxicity

  • James E. Gibson
Part of the Progress in Analytical Chemistry book series (PAC)


Drugs and other chemicals may produce qualitatively and quantitatively different toxicologic effects in embryos, fetuses and newborns than in the adult of the same species. When such toxicity occurs during embryogenesis congenital malformations may result. On the other hand, agents which produce toxicity during late fetal development, or during the neonatal period, may impair development or produce toxicity qualitatively similar to that seen in the adult. During embryogenesis there are embryological and non-embryological factors which determine an organism’s susceptibility to an agent, such as the nature of the agent, the dose, and maternal physiology (Wilson, 1965). Agents which disrupt embryonic development may initially act at any of the processes essential for normal development, e.g., cell division, differential gene expression, changes in the surface properties and shapes of cells, or general cellular metabolism. Most organs have a period of particular susceptibility to teratogens which probably coincides with the early and critical developmental events for that organ. During the fetal and neonatal period, however, after differentiation of cells is largely completed, chemical toxicity may involve interference with cell growth.


Newborn Mouse Placental Transfer Aldehyde Oxidase Newborn Animal Biotransformation Reaction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brock, N. and Hohorst, H.-J.: Ueber die Aktivierung von Cyclophosphamide in vivo und in vitro. Arzneimittel-Forschung 13: 1021–1031, 1963.Google Scholar
  2. Brock, N. and Hohorst, H.-J.: Metabolism of cyclophosphamide. Cancer 20: 900–904, 1967.CrossRefGoogle Scholar
  3. Bus, J.S., Short, R.D. and Gibson, J.E.: Effect of phenobarbital and SKF-525A on the toxicity, elimination and metabolism of cyclophosphamide in newborn mice. J. Pharmacol. Exp. Ther. 184: 749–756, 1973.Google Scholar
  4. Cohen, J.L. and Jao, J.J.: Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J. Pharmacol. Exp. Ther. 174: 206–210, 1970.Google Scholar
  5. Conney, A.H.: Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19: 317–366, 1967.Google Scholar
  6. Conners, T.A., Grover, P.L. and McLoughlin, A.M.: Micro-somal activation of cyclophosphamide in vivo. Biochem. Pharmacol. 19: 1533–1535, 1970.Google Scholar
  7. Fields, R.B., Gang, M., Kline, I., Venditti, J.M. and Waravdekar, V.S.: The effect of phenobarbital or 2diethylaminoethyl-2, 2-diphenylvalerate on the activation of cyclophosphamide in vivo. J. Pharmacol. Exp. Ther. 180: 475–483, 1972.Google Scholar
  8. Fouts, J.R.: Some studies and comments on hepatic and extra-hepatic microsomal toxication-detoxication systems. Environmental Health Perspectives: experimental issue. 2: 55–66, 1972.Google Scholar
  9. Fouts, J.R. and Adamson, R.H.: Drug metabolism in the newborn rabbit. Science (Washington) 129: 857–858, 1959.Google Scholar
  10. Fouts, J.R. and Devereux, T.R.: Developmental aspects of hepatic and extrahepatic drug-metabolizing enzyme systems: Microsomal enzymes and components in rabbit liver and lung during the first month of life. J. Pharmacol. Exp. Ther. 183: 458–468, 1972.Google Scholar
  11. Gerlinger, P.: Action du cyclophosphamide injecté à la mére sur la réalisation de la forme du corps des embryons de lapin. C. R. Seances Soc. Biol. Filiales 158: 2154–157, 1964.Google Scholar
  12. Gibson, J.E. and Becker, B.A.: Effect of phenobarbital and SKF-525A on the teratogenicity of cyclophosphamide in mice. Teratology 1: 393–398, 1968.CrossRefGoogle Scholar
  13. Gibson, J.E. and Becker, B.A.: The teratogenicity of cyclo- phosphamide in mice. Cancer Res. 28: 475–480, 1968.Google Scholar
  14. Gibson, J.E. and Becker, B.A.: Effect of phenobarbital and SKF-525A on placental transfer of cyclophosphamide in mice. J. Pharmacol. Exp. Ther. 177: 256–262, 1971.Google Scholar
  15. Gibson, J.E. and Becker, B.A.: Teratology of structural truncates of cyclophosphamide in mice. Teratology 4: 141–151, 1971.CrossRefGoogle Scholar
  16. Goldenthal, E.I.: A compilation of LD50 values in newborn and adult animals. Toxicol. Appl. Pharmacol. 18: 185–207, 1971.CrossRefGoogle Scholar
  17. Hackenberger, I., Kreybig, T. von: Vergleichende teratologische Untersuchungen bei der Maus und der Ratte. Arzneimittel-Forschung 15: 1456–1460, 1965.Google Scholar
  18. Hart, L.G., Adamson, R.H., Dixon, R.L. and Fouts, J.R.: Stimulation of hepatic microsomal drug metabolism in the newborn and fetal rabbit. J. Pharmacol. Exp. Ther. 137: 103–106, 1962.Google Scholar
  19. Hayes, F.D., Short, R.D. and Gibson, J.E.: A correlation between cyclophosphamide induced leukopenia in mice and the presence of alkylating metabolites. Proc. Soc. Exp. Biol. Med. 139: 417–421, 1972.CrossRefGoogle Scholar
  20. Henderson, P.T.: Metabolism of drugs in rat liver during the perinatal period. Biochem. Pharmacol. 20: 1225–1232, 1971.CrossRefGoogle Scholar
  21. Hill, D.L., Laster, W.R., Jr. and Struck, R.F.: Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite. Cancer Res. 32: 658–665, 1972.Google Scholar
  22. Jondorf, W.R., Maickel, R.P. and Brodie, B.B.: Inability of newborn mice and guinea pigs to metabolize drugs. Biochem. Pharmacol. 1: 352–354, 1959.CrossRefGoogle Scholar
  23. Kreybig, T. von: Die teratogene Wirkung von Cyclophosphamide wahrend der embryonalen Entwicklungsphase bei der Ratte. Naunyn-Schmeidegergs Arch. Pharmakol. 252: 173–195, 1965.CrossRefGoogle Scholar
  24. MacLeod, S.M., Renton, K.W. and Eade, N.R. Development of hepatic microsomal drug-oxidizing enzymes in immature male and female rats. J. Pharmacol. Exp. Ther. 183: 489–498, 1972.Google Scholar
  25. Murphy, M.L.: Teratogenic effects of growth inhibiting chemicals, including studies on thalidomide. Clin. Proc. Child. Hosp. D.C. 18: 307–322, 1962.Google Scholar
  26. Rauen, H.M. and Kramer, K.P.: Der Gesamtalkylantien Blutspiegel von Ratten nach Verabreichung von Cyclophosphamid and Acyclophosphamid. Arzneimittel-Forschung 14: 1066–1067, 1964.Google Scholar
  27. Roberts, J.J., Brent, T.P. and Crathorn, A.R.: The mechanism of the cytotoxic action of alkylating agents on mammalian cells. In P. N. Campbell (ed.), The Interaction of Drugs and Subcellular Components in Animal Cells, pp. 5–27, London: J. & A. Churchill, Ltd., 1968.Google Scholar
  28. Shoji, R. and Ohzu, E.: Effect of endoxan on developing mouse embryos. J. Fac. Sci. Hokkaido Univ. Serv. VI Zool. 15: 662–665, 1965.Google Scholar
  29. Short, C.R. and Davis, L.E.: Perinatal development of drug- metabolizing enzyme activity in swine. J. Pharmacol. Exp. Ther. 174: 185–196, 1970.Google Scholar
  30. Short, R.D. and Gibson, J.E.: Development of cyclophosphamide activation and its implications in perinatal toxicity to mice. Toxicol. Appl. Pharmacol. 19: 103–110, 1971.CrossRefGoogle Scholar
  31. Short, R.D. and Gibson, J.E.: The effects of cyclophosphamide and nor-nitrogen mustard administration to one-day-old mice. Experientia (Basel) 27: 805–806, 1971.Google Scholar
  32. Short, R.D., Rao, K.S. and Gibson, J.E.: The in vivo biosynthesis of DNA, RNA, and proteins by mouse embryos after a teratogenic dose of cyclophosphamide. Teratology 6: 129–137, 1972.CrossRefGoogle Scholar
  33. Short, R.D. and Gibson, J.E.: Biosynthesis of deoxyribonucleic acid, ribonucleic acid and protein in vivo by neonatal mice after a toxic dose of cyclophosphamide. Biochem. Pharmacol. 22: 3181–3188, 1973.CrossRefGoogle Scholar
  34. Sladek, N.E.: Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Canc. Res. 32: 535–542, 1972.Google Scholar
  35. Soyka, L.F.: Determinants of hepatic aminopyrine demethylase activity. Biochem. Pharmacol. 18: 1029–1038, 1969.CrossRefGoogle Scholar
  36. Wheeler, G.P. and Alexander, J.A.: Effects of nitrogen mustard and cyclophosphamide upon the synthesis of DNA in vivo and in cell free preparations. Canc. Res. 29: 98–109, 1969.Google Scholar
  37. Wilson, J.G.: Teratogenic interaction of chemical agents in the rat. J. Pharmacol. Exp. Ther. 144: 420–436, 1964.Google Scholar
  38. Wilson, J.G.: Embryological considerations in teratology. In J. G. Wilson and J. Warkany (eds.), Teratology Principles and Techniques, pp. 251–278, Chicago: The University of Chicago Press, 1965.Google Scholar
  39. Wilson, J.T.: Alteration of normal development of drug metabolism by injection of growth hormone. Nature (London) 225: 861–863, 1970.Google Scholar

Copyright information

© Springer Science+Business Media New York 1974

Authors and Affiliations

  • James E. Gibson
    • 1
  1. 1.Department of PharmacologyMichigan State UniversityEast LansingUSA

Personalised recommendations